# DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

Study · id `cardio:ct-nct07275515` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07275515](<https://clinicaltrials.gov/study/NCT07275515>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07275515

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 192 participants.

## Technical summary

Registry record NCT07275515. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-19 (actual); primary completion 2029-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 192 participants (planned count; ClinicalTrials.gov record NCT07275515, source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)
- Started: 2026-05-19 (actual) (ClinicalTrials.gov record NCT07275515, source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)
- Primary completion: 2029-05 (anticipated) (ClinicalTrials.gov record NCT07275515, source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)
- Completion: 2029-05 (anticipated) (ClinicalTrials.gov record NCT07275515, source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT07275515, source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07275515-2026-05-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL
- Acronym: DARLENE
- Condition: Stroke
- Intervention (Drug): DRF
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Lille
- Lead sponsor class: OTHER
- Collaborator: Ministère de la Santé
- Collaborator class: AMBIG

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: University Hospital, Lille (`cardio:org-university-hospital-lille`)

## Provenance

Content hash: 318592d580a8195feb210e6541c1fb738cb0d7714ed0fba92bb6b85e219d5690
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
